A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality

Since December 2019, coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has changed our lives. Elderly and those with comorbidities represent the vast majority of patients hospitalized with severe COVID-19 symptoms, including a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Emerging microbes & infections 2021-01, Vol.10 (1), p.2256-2263
Hauptverfasser:	Camelo, Serge, Latil, Mathilde, Agus, Sam, Dioh, Waly, Veillet, Stanislas, Lafont, René, Dilda, Pierre J.
Format:	Artikel
Sprache:	eng
Schlagworte:	ACE2 aging Angiotensin-Converting Enzyme 2 - antagonists & inhibitors Angiotensin-Converting Enzyme 2 - genetics Angiotensin-Converting Enzyme 2 - immunology Angiotensin-Converting Enzyme Inhibitors - therapeutic use Anti-Inflammatory Agents - therapeutic use Antiviral Agents - therapeutic use antivirals COVID-19 COVID-19 - immunology COVID-19 - mortality COVID-19 - virology COVID-19 Drug Treatment dexamethasone Emerging and Re-Emerging Coronaviruses Human health and pathology Humans Life Sciences mas receptor renin-angiotensin system Review SARS-CoV-2 - drug effects SARS-CoV-2 - genetics SARS-CoV-2 - physiology Tocilizumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!